Interleukin-6 promotes arthritis and joint deformation in patients
with systemic lupus erythematosus;
Eilertsen GO, Nikolaisen C, Becker Merok A, Nossent JC;
Lupus (Mar 2011)

The underlying mechanisms for the subsets of self-limiting,
intermittent or chronic and deforming arthritis in systemic lupus
erythematosus (SLE) are not well understood. We performed a cross-
sectional analysis of pro-inflammatory cytokines (IL-1ОІ, IL-2, IL-6,
IL-8 and TNF-О±) and joint status in 47 SLE patients (79% females, age
42 years, disease duration 8.6 years). All cytokines levels were
significantly elevated in SLE patients compared with controls, but
only IL-2 and IL-8 levels were higher than in patients with rheumatoid
arthritis. SLE patients with ongoing synovitis (19%) and joint
deformities (11%) had increased erythrocyte sedimentation rate (ESR),
IL-6 and anti-dsDNA Ab levels. IL-6 levels correlated with ESR, anti-
dsDNA Ab and haemoglobin, but not with C-reactive protein levels.
Arthritis constitutes a considerable burden of disease in SLE over
time, and joint deformations are associated with longstanding disease
and arthritis flare rates. IL-6 is a potential biomarker and
therapeutic target in the prevention of joint damage in SLE arthritis.


Alpha tocopherol supplementation decreases serum C-reactive protein
and monocyte interleukin-6 levels in normal volunteers and type 2
diabetic patients
Alternative Medicine Review, Feb, 2001 by Julie Jurenka
Devaraj S, Jialal I. Free Radic Biol Med

Type 2 diabetic subjects have an increased propensity to premature
atherosclerosis. Alpha tocopherol (AT), a potent antioxidant, has
several anti-atherogenic effects. There is scanty data on AT
supplementation on inflammation in Type 2 diabetic subjects. The aim
of the study was to test the effect of RRR-AT supplementation (1200
d) on plasma C-reactive protein (CRP) and interleukin-6 (IL-6)
from activated monocyte in Type 2 diabetic patients with and without
macrovascular complications compared to matched controls. The
volunteers comprised Type 2 diabetic subjects with macrovascular
disease (DM2-MV, n = 23), Type 2 diabetic subjects without
macrovascular complications (DM2, n = 24), and matched controls (C, n
= 25). Plasma high sensitive CRP (Hs-CRP) and Monocyte IL-6 were
assayed at baseline, following 3 months of supplementation and
following a 2 month washout phase. DM2-MV subjects have elevated
and monocyte IL-6 compared to controls. AT supplementation
significantly lowered levels of C-reactive protein and monocyte
interleukin-6 in all three groups. In conclusion, AT therapy
inflammation in diabetic patients and controls and could be an
adjunctive therapy in the prevention of atherosclerosis.

COPYRIGHT 2001 Thorne Research Inc.
COPYRIGHT 2001 Gale Group


Who loves ya.

Jesus Was A Vegetarian!

Man Is A Herbivore!